Biomimetic nanoparticles for effective mild temperature photothermal therapy and multimodal imaging

J Control Release. 2022 Jul:347:270-281. doi: 10.1016/j.jconrel.2022.05.010. Epub 2022 May 13.

Abstract

Downregulation of adenosine triphosphate (ATP)-dependent heat shock proteins (HSPs) can significantly reduce the tumorigenicity of cancer cells and overcome heat endurance to achieve high-performance mild temperature (≤45 °C) photothermal therapy (PTT). Herein, we designed and constructed 4T1 cancer cell membrane-coated, lonidamine (LN)-loaded and DL-menthol (DLM)-loaded hollow mesoporous Prussian blue nanoparticles (PBLM@CCM NPs). DLM with mild phase change characteristics served as a plugging agent to avoid early leakage and allow thermally controllable release of LN, which enabled selective intracellular delivery of LN to reduce the HSPs and overcome the heat endurance in PTT by inhibiting the generation of intracellular ATP. The biocompatible PBLM@CCM NPs with good tumor targeting efficiency achieved high-efficiency mild temperature PTT. Meanwhile, PBLM@CCM NPs could allow photoacoustic (PA) imaging and generate heat to promote the phase change of DLM for ultrasound (US) imaging, which is of great value for future clinical translational studies.

Keywords: Heat endurance; Heat shock proteins; Hollow mesoporous Prussian blue nanoparticles; Mild temperature photothermal therapy; Multimodal imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate
  • Biomimetics
  • Cell Line, Tumor
  • Humans
  • Hyperthermia, Induced* / methods
  • Multimodal Imaging
  • Nanoparticles* / therapeutic use
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / therapy
  • Phototherapy / methods
  • Photothermal Therapy
  • Temperature

Substances

  • Adenosine Triphosphate